Cd34 / Hla - Dr Antigen Expression In The Expression And Significance Of Acute Myeloid Leukemia

Objective To investigate the expression of surface differentiation CD34 and HLA-DR antigen and their the clinical significance through an analysis of 65 cases of patients with acute myeloid leukemia(AML).Analysia character of co-expression of CD34/HLA-DR in AML.To provide a reference for clinical work options with chemotherapy,such as complete remission rate of the disease for AML.Methods Flow cytometery(FCM)was used to detect the positive expression rate of CD34/HLA-DR in bone marrow of 65 patients with AML who were selected from 2010 to 2011 in our hospital,38 cases were complete remission with chemotherapy. Clinical features such as peripheral white blood cell count, hemoglobin, platelet count, the proportion of the blasts in bone marrow were observed. The curative effect and prognosis of AML patients were statistical analysis between CD34/HLA-DR co-expression and no CD34/HLA-DR co-expression.Results①There was no significantly difference (P> 0.05) between CD34/HLA-DR co-expression and no CD34/HLA-DR co-expression in peripheral white blood cell count, hemoglobin, platelet count and the proportion of the blasts in bone marrow.②The complete remission (CR) rate of CD34/HLA-DR co-expression in AML patients was 38.71%(12/31) Which was significantly lower than no CD34/HLA-DR co-expression in AML patients (76.47%, PO.05).Conclusion①CD34/HLA-DR co-expression had no significantly difference in the clinical characteristics of AML.②The co-expression of CD34/HLA-DR decreased the chemotherapy effective, may be used as an index in evaluating patients’s prognosis with AML.